WARRENDALE, Pa., Aug. 7 /PRNewswire/ -- MEDRAD, INC., announced today the
first installation of its Intego(TM) PET Infusion System at the University of
Pittsburgh Medical Center (UPMC), Hillman Cancer Center. To achieve this
milestone, MEDRAD has partnered with IBA Molecular which will supply UPMC with
Fluorodeoxyglucose (FDG) in a multi-dose vial housed in a specially-designed
Tungsten vial shield. Use of this innovative system minimizes the need to
manually prepare and handle individual FDG doses, significantly reducing
potential radiation exposure to hospital personnel.
The Intego System automates the administration of FDG for Positron
Emission Tomography/Computed Tomography (PET/CT) imaging procedures. By
automating and controlling FDG dosing and infusion, the Intego System
precisely, flexibly, safely, and easily administers FDG to patients throughout
the day.
The Intego System automatically extracts a patient dose from a multi-dose
vial and administers the dose, via infusion, directly to the patient,
minimizing the need for manual dose preparation and associated handling, as
well as protecting the technologist from the corresponding radiation exposure.
With the Intego System's dose-on-demand capability, the prescribed dose may be
administered when the patient and technologist are ready, enabling
technologists to easily and efficiently respond to schedule changes, patient
delays, and add-on patients.
"MEDRAD will improve the quality of healthcare for patients and will
enhance procedure safety for clinicians at Intego's first clinical site, UPMC,
Hillman Cancer Center. The partnership with IBA Molecular helps us achieve
this part of our mission," said Doug Descalzi, executive director, MEDRAD
Molecular Imaging.
"IBA is very pleased to support this first clinical installation of the
Intego System. We are excited to be a part of improving the way FDG is
delivered and administered. This innovation will improve safety for
technologists and physicians performing Positron Emission Tomography," said
Anwer Rizvi, president, IBA Molecular.
MEDRAD recently received U.S. FDA 510(k) clearance for the Intego PET
Infusion System.
About MEDRAD
MEDRAD, INC., is a worldwide leading provider of medical devices and
services that enable and enhance imaging procedures of the human body. Used
in diagnostic imaging, MEDRAD's product offerings include a comprehensive line
of vascular injection systems, magnetic resonance (MR) surface coils and
patient care products, and equipment services. Total 2007 revenues were $525
million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality
Award, the top honor a U.S. company can receive for quality and business
excellence. The company's world headquarters is near Pittsburgh,
Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG. For
more information, visit http://www.medrad.com.
The Bayer Group is a global enterprise with core competencies in the
fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a
subsidiary of Bayer AG, is one of the world's leading, innovative companies in
the healthcare and medical products industry and is based in Leverkusen,
Germany. The company combines the global activities of the Animal Health,
Consumer Care, Diabetes Care and Pharmaceuticals divisions. The
pharmaceuticals business operates under the name Bayer Schering Pharma AG.
Bayer HealthCare's aim is to discover and manufacture products that will
improve human and animal health worldwide. Find more information at
http://www.bayerhealthcare.com.
About IBA Molecular
IBA Molecular is a committed partner in molecular imaging. Offering a
global distribution of the most advanced cyclotron solutions, the most
reliable radiopharmaceutical distribution network and the most novel research
radionuclides, so that together we can make a difference in the lives of
patients. Contact us to learn how our superior service, superior solutions
and superior science can help build your PET business.
http://www.iba-molecular.com
Certain statements in this press release that are neither reported
financial results nor other historical information are forward-looking
statements, including but not limited to, statements that are predictions of
or indicate future events, trends, plans or objectives. Undue reliance should
not be placed on such statements because, by their nature, they are subject to
known and unknown risks and uncertainties and can be affected by other factors
that could cause actual results and MEDRAD's plans and objectives to differ
materially from those expressed or implied in the forward-looking statements.
MEDRAD, INC., undertakes no obligation to update publicly or revise any of
these forward-looking statements, whether to reflect new information or future
events or circumstances or otherwise.
.gif)
